Why combine a scaffold with MSCs for a focal hip defect

Injecting a collagen scaffold into a focal hip cartilage defect addresses the structural problem — it fills the lesion and provides a matrix for repair. The harder question is: what populates it? Adult articular cartilage carries no blood vessels and no nerve supply, so when a focal defect forms on the femoral head or acetabulum it cannot draw on the healing cascade that repairs bone or muscle. The scaffold must instead rely on progenitor cells — including mesenchymal stem cells (MSCs) — migrating in from the synovial fluid and adjacent tissue.

In a well-vascularised joint that process may be adequate. In the hip, a deep ball-and-socket cavity with relatively limited synovial turnover, the journey from circulating progenitor to fully colonised scaffold is slower and less assured. An acellular implant placed here depends on chance proximity of enough cells arriving at the right time.

Co-delivering the patient's own autologous MSCs directly into the scaffold at the moment of injection is a logical response to that bottleneck: instead of waiting for host cells to migrate in, a chondrogenic population is placed inside the matrix from the outset, potentially shortening the cellularisation window. This is the core rationale for combining an injectable collagen scaffold — ChondroFiller injection — with autologous MSC micrografting in a single outpatient sitting.

The concept draws on separately evidenced components. Neither is experimental in isolation; the combination for focal hip defects is an emerging, image-guided approach supported by component-level evidence rather than a completed randomised trial.

How ChondroFiller injection works in the hip joint

Delivered as an outpatient injection under ultrasound or fluoroscopic guidance — not as arthroscopic or theatre-based surgery — ChondroFiller injection is placed directly into a focal chondral lesion without general anaesthesia or hospital admission.

The scaffold's active material is Type I collagen isolated from rat-tail tendon by gentle acid extraction rather than enzymatic digestion. That distinction matters: preserving the telopeptide end-regions intact enables authentic physiological cross-linking at body temperature, producing a three-dimensional fibrillar matrix that closely mimics native cartilage architecture.

Once in position, the scaffold serves two roles simultaneously. Mechanically, it fills the defect void and cushions the lesion surface under load. Biologically, it acts as a chemotactic template: the native collagen fibril network actively draws host progenitor cells — including MSCs from the synovial fluid and adjacent tissue — into the matrix to adhere and differentiate toward a chondral phenotype. This is matrix-induced chondrogenesis: the scaffold creates the conditions for repair rather than delivering pre-formed cartilage.

The clinical target is focal Grade III or IV articular cartilage defects with intact surrounding borders, typically up to 3 cm² (extendable to 6 cm² per the published clinical evaluation report). Perez-Carro et al. (2021) reported ChondroFiller use specifically in the hip joint, establishing a published clinical precedent for focal hip chondral lesions. Structural outcomes in published European series — predominantly from knee cohorts — show MOCART scores progressing from 65.3 at four weeks to 81.6 at twelve months, with established series recording 81.6–84.3; published hip-specific data report modified Harris Hip Score gains of approximately 30 points.

What autologous MSCs contribute to scaffold cellularisation

Mesenchymal stromal cells — MSCs — are the body's own tissue-repair progenitors, found naturally in bone marrow, fat, synovium, and other connective tissues. Given the right biochemical signals, they can differentiate into chondrocytes: the specialised cells responsible for producing and maintaining the cartilage matrix. That capacity is precisely why they feature in scaffold-based cartilage repair strategies.

Autologous preparations — cells taken from the patient's own tissue — are preferred over allogeneic (donor-derived) alternatives for two straightforward reasons: there is no rejection risk, and the published evidence base supporting their safety and efficacy is substantially stronger than for donor-derived equivalents.

Source tissue also influences outcome. Research comparing harvesting sites suggests that synovium-derived MSCs show the strongest chondrogenic differentiation potential, outperforming bone-marrow-derived and adipose-derived preparations in cartilage-forming assays. In clinical practice, the appropriate source is determined at the time of assessment.

Within the NanoACi protocol, the autologous cell component is prepared using the Rigenera AMT system, producing Mytocel MSK — an autologous micrograft preparation enriched with chondrogenic progenitors. Crucially, this is a point-of-care processing step, not a pharmaceutical manufacture: preparation and delivery take place within the same outpatient sitting, with no cell-culture interval between harvest and injection.

The proposed benefit follows directly. Rather than relying on host progenitors to in-migrate into the scaffold after placement — a process that is slower and less assured in the relatively enclosed hip joint environment — co-injecting Mytocel MSK places a chondrogenic cell population inside the matrix from the outset. Evidence suggests this may improve the rate and consistency of scaffold cellularisation, though it should not be taken as a guarantee of cartilage regrowth.

What the current evidence shows — and where it ends

The evidence sits at different levels for each element, and that distinction matters for any clinical decision.

ChondroFiller injection — prospective cohort data

Jerosch et al.'s post-market clinical follow-up study recorded a mean IKDC improvement of 32.4 points, sustained and slightly increased at three-year follow-up, with patients reaching a mean score of 80. The 16.7-point minimal clinically important difference provides a useful benchmark: a gain of more than 30 points places outcomes firmly above it. Across more than 20,000 implantations, the reported complaint rate sits at approximately 0.06%. These figures come from European cohort studies, predominantly in the knee, with Perez-Carro (2021) establishing a published clinical precedent for ChondroFiller use specifically in the hip joint.

Scaffold plus cells — Weninger et al. (2025)

The most direct published support for combining scaffold with autologous cells comes from Weninger et al. (2025), reporting outcomes in Grade IV joint disease treated with scaffold and autologous cell co-administration. That study validates the combination concept clinically and is cited as the pivotal evidence underpinning the NanoACi protocol design. The joint involved, however, was not the hip.

What is not yet evidenced

The full three-part NanoACi protocol — ChondroFiller injection, Mytocel MSK, and Arthrozheal PRF — has not been evaluated in a randomised controlled trial. Its authors state this directly: the components are individually evidenced and the scaffold-plus-cells pairing has published clinical support, but the three-part combination in the hip joint remains at a rationally designed and prospectively observed stage. The NanoACi 100 registry is accumulating one hundred consecutive cases with pre-agreed imaging and functional endpoints; results are embargoed until the full dataset is complete.

The plain summary: ChondroFiller injection has a solid published record as a standalone treatment; combining scaffold with autologous cells has clinical support in published literature; the complete three-part combination in the hip has not been tested in a randomised trial and is not yet standard of care.

Key uncertainties and the NanoACi outcomes registry

Several specific clinical questions remain genuinely open, distinct from the broader evidence gaps covered above.

The optimal MSC source for the hip joint has not been established. Synovium-derived cells show the strongest chondrogenic differentiation potential in comparative studies, but synovial harvest carries practical access challenges — particularly in a joint already compromised by cartilage damage. Bone-marrow-derived and adipose-derived preparations are more straightforwardly obtained, yet their chondrogenic output may be lower. Which source best serves the focal hip environment, and under what patient-specific circumstances, has not been settled in peer-reviewed hip literature.

Beyond source, the required cell dose, concentration, and timing of MSC co-injection relative to scaffold setting remain undefined for the hip in published studies. These are not minor technical details: they affect how thoroughly the scaffold is seeded and whether chondrogenic differentiation proceeds in a sustained or transient way.

Long-term durability of the repair tissue is a further open question, even for ChondroFiller injection used alone in the hip; published hip-specific follow-up data beyond three years is limited.

The NanoACi 100 registry — with pre-agreed imaging and patient-reported outcome measures across one hundred consecutive cases — is the structured evidence pathway being built to address these questions. Until those results are published, the most accurate framing is that the clinical rationale is sound and the component evidence encouraging, with hip-specific prospective data still accumulating.

Who this approach suits and what the hip pathway looks like

Suitable candidates share a specific clinical profile: a symptomatic, isolated Grade III or IV chondral lesion on the femoral head or acetabulum, with healthy articular cartilage bordering the defect on all sides. Most are younger or middle-aged adults — typically under 55 — who have already tried conservative management (physiotherapy, analgesia, or biologic injections) without sufficient relief. Patients with diffuse hip osteoarthritis, where cartilage loss is widespread rather than focal, are not candidates for this approach; their pathway leads toward hip preservation strategies or, in advanced disease, joint replacement.

In practice, the outpatient visit involves ultrasound-guided placement of the collagen scaffold — with or without co-administered autologous micrografts — into the focal lesion under local anaesthesia, with no hospital admission or theatre booking required. The transition from arthroscopic implant to image-guided injection is precisely what makes this feasible at the hip, a joint where open or keyhole cartilage surgery carries substantially more logistical and recovery burden.

Expectation-setting is important. ChondroFiller injection has a published track record as a standalone treatment; the addition of autologous micrografts has published support for the scaffold-plus-cells concept in grade IV disease; but the complete combined protocol in the hip joint is still accumulating prospective data, and it is not an established, trial-proven cure. Patients considering this pathway are at the frontier of regenerative hip care, not at the end of a long-settled evidence base.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without GP referral for hip assessment at Sleaford and Grantham — a practical starting point for anyone wanting a consultant opinion on whether their hip lesion is suitable.

1. [1] Mesenchymal Stem Cell — Wikipedia. https://en.wikipedia.org/?curid=30876356 https://en.wikipedia.org/?curid=30876356